Charles River Laboratories has invested in Resero Analytics™, a software company focused on providing solutions to the biopharmaceutical industry to harness its data.
As part of its investment, Charles River will collaborate with Resero Analytics and is now the exclusive contract research organization (CRO) partner for TurboToxicology™, a report generation tool that enables faster delivery of high-quality reports.
TurboToxicology analyzes nonclinical data in Standard for Exchange of Nonclinical Data (SEND) and other structured data formats, and conducts statistical analyses, applies proprietary algorithms, and displays study results via visually appealing user interfaces. The tool then formats the data, in concert with the scientist’s interpretation, to generate a complete written report that is inclusive of text, tables, figures, and legends.
“By implementing solutions that increase efficiency in reporting, our goal is to give our clients the gift of time. By alleviating some of the upfront administrative work, TurboToxicology’s report generation tool will allow time for greater focus on other areas of drug development,” said Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River.
TurboToxicology enables the efficient production of consistent formatted reports, helping to accelerate this step in the drug development process and thereby accelerating Investigational New Drug (IND) or New Drug Approval (NDA) submissions.
SEND is an implementation of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) that provides a framework for the standardized, electronic representation of individual research model study data. SEND is intended to increase the effectiveness and efficiency of data review for regulatory submissions.
Leveraging structured data, including SEND, allows TurboToxicology to expedite interpretation and ensure consistency across authors and sites producing toxicology reports, while enabling sponsor companies to make quicker decisions by providing robust data early in the reporting process. This time savings is essential as sponsor companies work to move potential therapeutics through the drug development pipeline efficiently, without sacrificing quality.
“With a global network, and the most robust portfolio in preclinical research, Charles River was the clear CRO partner of choice for TurboToxicology,” Dave Watson, PhD, MBA, Founder & CEO at Resero Analytics.